AstraZeneca FY2025 EPS Forecast Raised by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Research analysts at Zacks Research raised their FY2025 earnings estimates for AstraZeneca in a report released on Monday, February 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.59 per share for the year, up from their previous forecast of $4.58. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Zacks Research also issued estimates for AstraZeneca’s Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.09 EPS.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the company posted $0.87 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis.

Other research analysts have also recently issued research reports about the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 2.9 %

NASDAQ:AZN opened at $70.93 on Wednesday. The firm has a market capitalization of $219.96 billion, a price-to-earnings ratio of 33.94, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a fifty day moving average price of $67.20 and a 200-day moving average price of $73.72. AstraZeneca has a one year low of $60.47 and a one year high of $87.68.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can increased its stake in AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after purchasing an additional 1,605,758 shares during the period. Franklin Resources Inc. increased its stake in AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after buying an additional 1,522,715 shares during the period. Erste Asset Management GmbH acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $72,437,000. Proficio Capital Partners LLC grew its stake in shares of AstraZeneca by 6,835.8% in the fourth quarter. Proficio Capital Partners LLC now owns 708,009 shares of the company’s stock worth $46,389,000 after acquiring an additional 697,801 shares in the last quarter. Finally, Manning & Napier Advisors LLC increased its holdings in AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock worth $245,407,000 after purchasing an additional 564,297 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.